THYROCARE TECHNOLOGIES LIMITED Thyrocare Technologies Limited Stock NSE India S.E.
Equities
THYROCARE
INE594H01019
Healthcare Facilities & Services
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 655 INR | -0.73% |
|
+3.57% | +1.78% |
| Sales 2024 * | 5.65B 67.75M | Sales 2025 * | 6.34B 76.02M | Capitalization | 34.51B 414M |
|---|---|---|---|---|---|
| Net income 2024 * | 747M 8.96M | Net income 2025 * | 906M 10.87M | EV / Sales 2024 * | 6.11 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 5.44 x |
| P/E ratio 2024 * |
46.2
x | P/E ratio 2025 * |
38.1
x | Employees | 1,645 |
| Yield 2024 * |
1.3% | Yield 2025 * |
1.58% | Free-Float | 27.38% |
More Fundamentals
* Assessed data
More news
Latest transcript on Thyrocare Technologies Limited
| 1 day | -0.73% | ||
| 1 week | +3.57% | ||
| Current month | +11.03% | ||
| 1 month | +12.20% | ||
| 3 months | +4.74% | ||
| 6 months | +24.64% | ||
| Current year | +1.78% |
1 week
627.85
682.10
1 month
560.00682.10
Current year
554.10722.65
1 year
439.00722.65
3 years
415.401 465.00
5 years
407.151 465.00
10 years
407.151 465.00
| Managers | Title | Age | Since |
|---|---|---|---|
Rahul Guha
CEO | Chief Executive Officer | - | 22-05-03 |
| Director of Finance/CFO | - | 23-08-08 | |
Ramjee Dorai
CMP | Compliance Officer | 67 | 14-08-17 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 64 | 14-08-20 | |
| Director/Board Member | 54 | 14-09-19 | |
| Director/Board Member | - | 21-10-05 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 655 | -0.73% | 48,931 |
| 24-04-25 | 659.8 | -0.02% | 39,007 |
| 24-04-24 | 660 | +2.42% | 106,905 |
| 24-04-23 | 644.4 | +0.01% | 39,106 |
| 24-04-22 | 644.3 | +1.88% | 68,369 |
Delayed Quote NSE India S.E., April 26, 2024 at 07:43 am EDT
More quotes
Thyrocare Technologies Limited is an India-based healthcare services provider in diagnostic area. The Company has diagnostic chains that conduct a range of medical diagnostic tests and profiles of tests that is focused on early detection and management of health disorders and diseases. The Company's segments include Diagnostic Testing Services, Imaging Services and Others. The Diagnostic Testing Services segment includes diagnostic and testing services, selling of consumables used for collection and promotion of pathology. The Imaging Services includes diagnostic and imaging services, selling of radio-pharmaceutical, selling of consumables for reporting. The Others segment include the sale of testing equipment and consumables, and selling of glucometer and glucostrips under the brand, Sugarscan. The Company has a centralized fully automated diagnostic testing laboratory, regional processing laboratories, a medical cyclotron facility and PET-CT facilities across India.
Calendar
2024-05-02
- Q4 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
651.7
INR
Average target price
727.5
INR
Spread / Average Target
+11.63%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -17.89% | 8.36B | |
| +39.20% | 3.6B | |
| -39.11% | 2.73B | |
| -8.06% | 2.47B | |
| -7.35% | 2.32B | |
| -12.61% | 1.77B | |
| -19.01% | 1.55B | |
| -40.66% | 1.22B | |
| +7.56% | 1.09B |
- Stock Market
- Equities
- THYROCARE Stock
- THYROCARE Stock
